Jonathan Licht and Keith McCrae to lead new Blood specialty journals

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Clinical Trials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced.

July 10, 2026

Vol.52 No.27

By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo

Clinical Roundup

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Results from the phase I/II multicenter international CADENZA trial, led by researchers at the University of Texas MD Anderson Cancer Center, show that 75% of patients with blastic plasmacytoid dendritic cell neoplasm who were treated with the antibody-drug conjugate pivekimab sunirine had a complete response.

February 20, 2026

Vol.52 No.07

In Brief

University of York awarded £2.5 million to study blood cancers in the U.K.

Researchers at the University of York have received a £2.5 million boost from Cancer Research U.K., helping to transform future care for people diagnosed with blood cancers.

February 06, 2026

Vol.52 No.05

Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer.

ASCO publishes guideline on treating pregnant women with blood cancers

A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.

December 19, 2025

Vol.51 No.46

Jonathan Licht and Keith McCrae to lead new Blood specialty journals

YOU MAY BE INTERESTED IN

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

University of York awarded £2.5 million to study blood cancers in the U.K.

Blood Cancer United: A new name at the right moment

ASCO publishes guideline on treating pregnant women with blood cancers

Renew today!

Subscriber content

Never miss an issue!

Login

Jonathan Licht and Keith McCrae to lead new Blood specialty journals

YOU MAY BE INTERESTED IN

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Saving Western Kenya’s pediatric blood cancer patientsHow flow cytometry is changing the diagnostic landscape

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

University of York awarded £2.5 million to study blood cancers in the U.K.

Blood Cancer United: A new name at the right moment

ASCO publishes guideline on treating pregnant women with blood cancers

Never miss an issue!

Login

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape